Teacher Retirement System of Texas Sells 2,352 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Teacher Retirement System of Texas reduced its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 8.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,088 shares of the company’s stock after selling 2,352 shares during the quarter. Teacher Retirement System of Texas’ holdings in Vir Biotechnology were worth $156,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Baker BROS. Advisors LP bought a new position in shares of Vir Biotechnology during the fourth quarter worth $7,961,000. Artisan Partners Limited Partnership bought a new position in shares of Vir Biotechnology during the fourth quarter worth $6,742,000. Point72 Asset Management L.P. boosted its position in shares of Vir Biotechnology by 16,169.5% during the fourth quarter. Point72 Asset Management L.P. now owns 848,454 shares of the company’s stock worth $6,228,000 after acquiring an additional 843,239 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Vir Biotechnology by 58.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company’s stock worth $14,059,000 after acquiring an additional 703,360 shares during the last quarter. Finally, Millennium Management LLC boosted its position in shares of Vir Biotechnology by 55.3% during the fourth quarter. Millennium Management LLC now owns 1,715,083 shares of the company’s stock worth $12,589,000 after acquiring an additional 610,367 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Trading Down 1.5%

VIR opened at $5.41 on Monday. Vir Biotechnology, Inc. has a 12-month low of $4.32 and a 12-month high of $14.45. The firm has a market capitalization of $747.88 million, a PE ratio of -1.28 and a beta of 1.22. The firm has a 50 day moving average of $5.14 and a two-hundred day moving average of $6.95.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.05). Vir Biotechnology had a negative net margin of 2,769.04% and a negative return on equity of 47.46%. The firm had revenue of $3.03 million for the quarter, compared to analysts’ expectations of $8.59 million. During the same period last year, the firm earned ($0.48) earnings per share. Vir Biotechnology’s revenue for the quarter was down 94.6% compared to the same quarter last year. As a group, analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Raymond James Financial assumed coverage on shares of Vir Biotechnology in a research report on Friday, July 11th. They set an “outperform” rating for the company. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price objective on shares of Vir Biotechnology in a research report on Thursday, May 22nd. Finally, The Goldman Sachs Group lowered their price objective on shares of Vir Biotechnology from $28.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $30.25.

Insider Activity

In other Vir Biotechnology news, EVP Mark Eisner sold 6,796 shares of the business’s stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $5.47, for a total transaction of $37,174.12. Following the sale, the executive vice president directly owned 108,204 shares in the company, valued at $591,875.88. This represents a 5.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Vicki L. Sato sold 22,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $5.10, for a total value of $112,200.00. Following the completion of the sale, the director directly owned 1,298,391 shares of the company’s stock, valued at $6,621,794.10. The trade was a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,582 shares of company stock worth $185,150. Corporate insiders own 16.00% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).